Cargando…

Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances

Background: While current clinically administered anticoagulant medications have demonstrated effectiveness, they have also precipitated significant risks: severe bleeding complications including, but not limited to, gastrointestinal hemorrhaging and intracranial and other life-threatening major ble...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Yunqing, Hu, Yu, Tang, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300994/ https://www.ncbi.nlm.nih.gov/pubmed/37375813 http://dx.doi.org/10.3390/ph16060866

Ejemplares similares

Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
por: Heitmeier, Stefan, et al.
Publicado: (2022)

Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans
por: Piel, Isabel, et al.
Publicado: (2023)

Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia
por: Kar, Srabani, et al.
Publicado: (2020)

ThromboprophylaXIs with Factor XI/XIa inhibitors for venous thromboembolism
por: Porres-Aguilar, Mateo
Publicado: (2023)

Lignosulfonic Acid Sodium Is a Noncompetitive Inhibitor of Human Factor XIa
por: Kar, Srabani, et al.
Publicado: (2021)

Venous Thromboembolism Prophylaxis in Major Orthopedic Surgeries and Factor XIa Inhibitors
por: Jones, Aaryana, et al.
Publicado: (2023)

In Memorium of Dr. Bing Xia
por: Qian, Jiaming, et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa
por: Yi, B. Alexander, et al.
Publicado: (2021)

Designing Allosteric Inhibitors of Factor XIa. Lessons from the Interactions of Sulfated Pentagalloylglucopyranosides
por: Al-Horani, Rami A., et al.
Publicado: (2014)

Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

Decision making in xia2
por: Winter, Graeme, et al.
Publicado: (2013)

First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor
por: Perera, Vidya, et al.
Publicado: (2021)

Efficacy and safety of novel oral anticoagulants for the treatment of cancer-associated venous thromboembolism: protocol for an umbrella review of systematic reviews and meta-analyses
por: Xia, Yunqing, et al.
Publicado: (2023)

Allosteric Inhibition of Human Factor XIa: Discovery of Monosulfated Benzofurans as a Class of Promising Inhibitors
por: Argade, Malaika D., et al.
Publicado: (2014)

Corrigendum: First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor
Publicado: (2022)

Comparative Thrombin Generation in Animal Plasma: Sensitivity to Human Factor XIa and Tissue Factor
por: Liang, Yideng, et al.
Publicado: (2023)

Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis
por: Wang, Xinkang, et al.
Publicado: (2023)

Properdin (factor P) as a new target cleaved by factor XIa: Intrinsic coagulation at the crossroads with inflammation
por: Luo, Qi, et al.
Publicado: (2022)

Efficacy and Safety of Oral Factor XIa Inhibitors in Stroke Prevention: A Systematic Review and Meta-Analysis
por: Palaiodimou, Lina, et al.
Publicado: (2023)

Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-ij]Quinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa
por: Novichikhina, Nadezhda, et al.
Publicado: (2020)

Thrombogenic potential of picomolar coagulation factor XIa is mediated by thrombin wave propagation
por: Parunov, Leonid A., et al.
Publicado: (2023)

Xia-Gibbs Syndrome: A Review of Literature
por: Goyal, Chanan, et al.
Publicado: (2020)

Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa
por: Donkor, David A., et al.
Publicado: (2017)

AHDC1 missense mutations in Xia-Gibbs syndrome
por: Khayat, Michael M., et al.
Publicado: (2021)

Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys
por: Wong, Pancras C., et al.
Publicado: (2021)

Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease
por: Badimon, Juan J., et al.
Publicado: (2022)

Faktor-XIa-Hemmer: Antikoagulation auf höherem Sicherheitsniveau?
por: Overbeck, Peter, et al.
Publicado: (2022)

Sensitive Measurement of Clinically Relevant Factor VIII Levels in Thrombin Generation Assays Requires Presence of Factor XIa
por: van de Berg, Tom W., et al.
Publicado: (2023)

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects
por: Chen, Rui, et al.
Publicado: (2022)

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
por: Thomas, Dirk, et al.
Publicado: (2021)

A Factor XIa Inhibitor Engineered from Banded Krait Venom Toxin: Efficacy and Safety in Rodent Models of Arterial and Venous Thrombosis
por: Chng, Wei Seng, et al.
Publicado: (2022)

Two Chinese Xia‐Gibbs syndrome patients with partial growth hormone deficiency
por: Cheng, Xinran, et al.
Publicado: (2019)

EP-7041, a Factor XIa Inhibitor as a Potential Antithrombotic Strategy in Extracorporeal Membrane Oxygenation: A Brief Report
por: Pollack, Charles V., et al.
Publicado: (2020)

Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders
por: Roehrig, Susanne, et al.
Publicado: (2023)

Fluorescent Activity-Based Probe To Image and Inhibit Factor XIa Activity in Human Plasma
por: Modrzycka, Sylwia, et al.
Publicado: (2023)

A Systematic Review of the Mysterious Caterpillar Fungus Ophiocordyceps sinensis in Dong-ChongXiaCao (冬蟲夏草 Dōng Chóng Xià Cǎo) and Related Bioactive Ingredients
por: Lo, Hui-Chen, et al.
Publicado: (2013)

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
por: Nowotny, Bettina, et al.
Publicado: (2022)

Fragment-Based Lead Generation of 5-Phenyl-1H-pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors
por: Wei, Qunchao, et al.
Publicado: (2018)

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
por: Wong, Pancras C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qtafum9fo72hta8jltvnko1ech